本页面由Tiger Trade Technology Pte. Ltd.提供服务

Inozyme Pharma

4.00
0.0000
成交量:- -
成交额:583.41万
市值:2.60亿
市盈率:-2.38
高:4.00
开:4.00
低:4.00
收:4.00
52周最高:6.24
52周最低:0.7210
股本:6,491.57万
流通股本:3,014.82万
量比:- -
换手率:- -
股息:- -
股息率:- -
每股收益(TTM):-1.6822
每股收益(LYR):-1.6243
净资产收益率:-141.69%
总资产收益率:-48.45%
市净率:8.17
市盈率(LYR):-2.46

数据加载中...

2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/12

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/02/07

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/05

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/01/16

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2023/11/14

SEC问询函

Form CORRESP - Correspondence
2023/11/07

重要事件披露

Form 8-K - Current report
2023/11/07

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/09/26

重要事件披露

Form 8-K - Current report
2023/08/11

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/08/08

重要事件披露

Form 8-K - Current report
2023/08/08

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/08/08

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/07/28

重要事件披露

Form 8-K - Current report
2023/07/26

重要事件披露

Form 8-K - Current report
2023/06/30

SEC问询函

Form CORRESP - Correspondence
2023/06/28

重要事件披露

Form 8-K - Current report
2023/06/15

重要事件披露

Form 8-K - Current report
2023/06/01

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/05/23

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]